We've Moved - https://cdph.ca.gov/

Welcome to the State of California 

Frequently-Asked Question related to Meningococcal Serogroup C Disease Outbreaks:
Which meningococcal vaccine is recommended For this outbreak?


Q. Which meningococcal vaccine is recommended for this outbreak?   

The meningococcal cases in this outbreak are due to N. meningitidis, serogroup C. Quadrivalent meningococcoal conjugate vaccines (MenACWY/MCV4), either Menactra® (Sanofi Pasteur) or Menveo® (GlaxoSmithKline), are recommended for use in this outbreak since they protect against serogroup C meningococcal disease.

Menactra® and Menveo® are licensed for persons through the age 55 years, but may be administered to persons 56 years of age and older. They are the preferred formulations for

     ·        all adults 55 years and younger 
     ·        adults 56 years and older  
   who were vaccinated previously with MenACWY vaccine or 
      o   for whom multiple doses of vaccine are anticipated, (e.g., persons with HIV infection or other risk factors)  
§  Boosters are recommended every 5 years for adults who remain at high risk.   
§  Persons with HIV infection, asplenia, or complement component deficiencies are recommended to receive a two-dose MenACWY primary series.   

Given the history of multiple outbreaks of meningococcal serogroup C disease in the MSM population, MenACWY may be given to MSMs 56 years and older at risk in the current outbreak and also might be preferable should they require additional doses during future outbreaks.

If MenACWY conjugate vaccine is not available, meningococcal polysaccharide vaccine (Menomune®) may be given to adults 56 years and older.

For more information, please see http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf



Source: Centers for Disease Control and Prevention. [Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)]. MMWR 2013;62(No. RR-2):[1-28].


Last modified on: 11/17/2016 11:46 AM